Two Biotechs I liked in 2016: Medivation and Portage Biotech

&" itemprop="articleBody">

“Those who have knowledge, don’t predict. Those who predict, don’t have knowledge.”  –  Lao Tzu, 6th Century BC Chinese Poet

 

In 2016 I made mention publicly of only two equities that I really liked, Medivation and Portage Biotech.

Medivation I started to Tweet about in early April 2016 (see screenshot below) as a good candidate to be taken over by the end of the year. The stock at the time was trading around $40US. I had an aggressive target of $80. Just 100 days later, Pfizer said it had agreed to buy Medivation Inc. for $81.50 a share, valuing the total company at about $14 billion.

Portage Biotech is a penny stock that trades on the OTCBB at around .13c. ($PTGEF)

Many of the same players that built Medivation from a penny stock microcap to a $14 billion market cap takeover in 12 years are involved in Portage Biotech. A few weeks ago, Portage subsidiary company Biohaven completed a financing for $80 Million.

With Medivation now merged, Portage continues to be a favorite heading into 2017.

I look forward to finding you some more gems as soon as we uncover them.

Happy investing,

AML

Recent Posts

No Comments Yet

Leave a Reply

Latest Posts
  • Marksmen Financed and Ready for Horizontal Well Completion – Update 17/04/2018

    Marksmen Energy is one of our favorite junior oil and gas ex…

  • IBR Q1 2018 Portfolio Update

    “Same Shit, Different Day” – Stephen King …

  • Betting on the Jockey 101

    Steve Jobs once said, “To me, ideas are worth nothing unless…

Internet Bull Report

Thank you for reading

Internet Bull Report is a financial newsletter that uncovers remarkable equities, primarily in the High Tech and Biotech sectors globally.

FOLLOW US ON

Subscribe to the IBR blog

Keep up to date with our latest news and recommendations by getting them straight to your inbox!

We will never spam you or give your email address to a third party.